Featured Stories

Strategy Felicity Thomas Strategy Felicity Thomas

Putting a Spotlight on Formulation Services

The CDMO model is evolving to incorporate more innovative approaches and specialist capacity as a result of the increasingly complex development pipeline. In this article, The Pharma Navigator editors provide a snapshot of some of the news from CDMOs helping innovators with their formulation requirements.

Read More
Strategy Felicity Thomas Strategy Felicity Thomas

Adapting to an Expedited Review Process

A new priority review program, unveiled by the FDA with the potential to dramatically reduce the regulatory review process for drug applications, will require increased agility, responsiveness, and readiness from CDMOs with less room for error.

Read More
Strategy Felicity Thomas Strategy Felicity Thomas

Novo Nordisk CEO Steps Down

The change to the company’s leadership has been expedited as a result of the difficult market conditions and drop in share price that the company has experienced since mid-2024.

Read More
Strategy Felicity Thomas Strategy Felicity Thomas

CPHI Americas 2025: Working End-to-End

The Pharma Navigator sits down with Mara Candido from Aenova to learn more about the one-stop-shop experience, benefits of working with an end-to-end service provider, how advanced formulation strategies can aid with bioavailability/solubility issues, and the company’s focus for this year’s CPHI Americas event.  

Read More
Strategy Felicity Thomas Strategy Felicity Thomas

CPHI Americas 2025: Meeting Biomanufacturing Demand

As demand for biologic drug substance manufacturing rises, The Pharma Navigator, chats with Carrie Bracco from Novartis Contract Manufacturing about how this trend is impacting service providers, the challenges facing CDMOs in the space, and the benefits of strategic partnerships.

Read More
Strategy Felicity Thomas Strategy Felicity Thomas

CPHI Americas 2025: A Growing Service Offering

In this interview with The Pharma Navigator, Dan Dobry from Bend Bioscience chats about the value of comprehensive end-to-end services, challenges and future trends for OSD CDMOs, and the company’s focus for this year’s CPHI Americas event.

Read More
Strategy Felicity Thomas Strategy Felicity Thomas

Riding the Oral GLP-1 Wave

As more innovators look to develop orally administered GLP-1s further demand will be placed onto CDMOs to provide the expertise and capabilities needed to support the next generation of these drugs.

Read More